title: Reversal of erythema multiforme major with cyclophosphamide and prednisone.
abstract: OBJECTIVE
  To report a case of erythema multiforme (EM) major treated with cyclophosphamide and prednisone.
  
  
  METHODS
  General medicine and dermatology consult services, Department of Veterans Affairs Medical Center.
  
  
  METHODS
  A 44-year-old man with C4-C5 quadriplegia developed a skin reaction characterized by a painful, generalized maculopapular rash, bullae, ulceronecrotic lesions, and mucosal and epidermal sloughing after taking trimethoprim/sulfamethoxazole. The patient was treated with intravenous cyclophosphamide 150 mg infused over 1 hour every 24 hours and oral prednisone 15 mg every 6 hours. After two doses of cyclophosphamide, formation of bullae and epidermal sloughing had ceased, and the erythema was markedly diminished. Cyclophosphamide was discontinued before the third dose because of evolving leukopenia. Prednisone therapy was continued until the patient was discharged on hospital day 5, at which time the dosage was tapered.
  
  
  CONCLUSIONS
  Cyclophosphamide has been used extensively for other dermatologic reactions. Relief of pain and regression of the lesions in our patient occurred more quickly than anticipated.
  
  
  CONCLUSIONS
  Treatment of EM major with cyclophosphamide combined with prednisone appeared to be highly successful in this patient. Cyclophosphamide may be an effective, empiric initial treatment in reversing EM major.
authors.affiliation: Pharmacy Service, Veterans Affairs Medical Center, Long Beach, CA 90822, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Eastham
authors.forename: J L
authors.initials: JL
authors.lastname: Segal
authors.forename: M F
authors.initials: MF
authors.lastname: Gómez
authors.forename: G W
authors.initials: GW
authors.lastname: Cole
mesh_terms: D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D011782:Quadriplegia / Q000150:complications; D013119:Spinal Cord Injuries / Q000150:complications; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects
chemical_list: D000477:Alkylating Agents; D000892:Anti-Infective Agents, Urinary; D000893:Anti-Inflammatory Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003520:Cyclophosphamide; D011241:Prednisone